Pharmaceutical Industrial Policy Committee Initiatives for Clinical Trials
As of September 1, 2024
| Company name | Activities related to intractable and rare diseases |
|---|---|
| Kyowa Kirin Co. | Creation of clinical evidence that contributes to the consideration of the degree of treatment requested
We are conducting research on the current status of routine medical care to examine the relationship between various patient backgrounds (age/sex/comorbidities/history of treatment, etc.) and outcomes (laboratory values/clinical symptoms [objective evaluation by healthcare professionals]/interview/PRO [subjective evaluation by patients/caregivers]) and to identify groups with large disease burden requiring further improvement of treatment. We are conducting research to identify groups with a high burden of disease that require further treatment improvement.
We are conducting studies to collect information on important treatment issues (complications, etc.) that do not occur frequently in rare diseases with low incidence and to clarify the association (improvement/unchanged, etc.) with current treatment by integrating clinical studies conducted in various countries. |